Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Durvalumab +2 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing if adding a new medication to durvalumab (a cancer immunotherapy) will work better than durvalumab alone to treat patients with lung cancer that has spread and cannot be removed by surgery, and who have not gotten worse after receiving standard chemotherapy and radiation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.